Found 12 resultsAuthor [ Title] Type Year
Filters: Author is Logan, B [Clear All Filters]
Etanercept, Mycophenolate, Denileukin, or Pentostatin Plus Corticosteroids for Acute Graft-Versus-Host Disease: A Randomized Phase 2 Trial from the Blood and Marrow Transplant Clinical Trials Network. Blood, 114, 511-517. presented at the 07/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19443659. (2009).
Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant, 20, 1530-1536. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24910380. (2014).
Grade III - IV Acute GvHD and Treatment-Related Mortality Are Reduced Among Recipients of Larger Numbers of Donor Naïve CD8+ T-cells and Plasmacytoid Dendritic Cell Precursors in Allogeneic BM Grafts from Unrelated Donors: Results from BMT CTN 0201. In 38th Annual EBMT (European Group for Blood and Marrow Transplantation). presented at the 01/04/2012, Geneva, Switzerland. Retrieved from http://www.congrex.ch/ebmt2012.html. (2012).
Graft-versus-Host Disease Treatment: Predictors of Survival. Biol Blood Marrow Transplant, 16, 1693-1699. presented at the 12/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20541024. (2010).
GVHD Biomarkers Measured During Treatment Independently Predict Response to Therapy and Survival: A Blood and Marrow Transplant Clinical Trials Network Study (Abstract). In . presented at the 2011, Paris, France. Retrieved from http://www.congrex.ch/ebmt2011/. (2011).
Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care In Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome*. Biol Blood Marrow Transplant, 20, 1566-1572. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24972249. (2014).
Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-Versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant, 16, 421-429. presented at the 03/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19925875. (2010).
Peripheral-Blood Stem Cells Versus Bone Marrow from Unrelated Donors. N Engl J Med, 367, 1487-1496. presented at the 10/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23075175. (2012).
Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT. Blood, 124, 1372-1377. presented at the 08/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24982504. (2014).
Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402. In 54th Annual ASH Meeting. presented at the 08/12/2012, Atlanta, GA. Retrieved from http://www.hematology.org/Meetings/Annual-Meeting/. (2012).
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant, 18, 1265-1272. presented at the 08/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22343376. (2012).
Use of Biological Assignment in Hematopoietic Stem Cell Transplantation Clinical Trials. Clin Trials, 5, 607-616. presented at the 12/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19029209. (2008).